Table 2. Treatment Persistence and Reason for Discontinuation.

	All Patients			ACPA+ and/or RF+ Patients
	Abatacept n=100	TNFi n=165	P-Value	Abatacept n=55	TNFi n=108	P-Value
Index Drug with 12 Months of Persistence, n (%)	83 (83.0)	109 (66.1)	0.003	46 (83.6)	70 (64.8)	0.012
Reason for Discontinuation (among patients who discontinued index treatment), n (%)			<0.001			0.007
Disease Progression (uncontrolled symptoms or on laboratory testing)	12 (26.7)	45 (44.1)		5 (20.8)	31 (49.2)
Adverse Effects of Medication	1 (2.2)	13 (12.8)		0 (0)	9 (14.3)
Insurance Coverage	8 (17.8)	15 (14.7)		6 (25.0)	7 (11.1)
Adherence Issues	1 (2.2)	0 (0)		1 (4.2)	0 (0)
Physician Preference	1 (2.2)	5 (4.9)		1 (4.2)	3 (4.8)
Patient Preference	4 (8.9)	6 (5.9)		3 (12.5)	2 (3.2)
Other Reasons	14 (31.1)	18 (17.7)		7 (29.2)	11 (17.5)
Unknown/Not Specified	4 (8.9)	0 (0)		1 (4.2)	0 (0)

Abbreviations: ACPA+, positive anti-cyclic citrullinated peptide antibodies; RF+, positive rheumatoid factor antibodies; TNFi, tumor necrosis factor inhibitor.